Pre NACIMRT (at enrollment) | n = 49 |
age (years) | 68.6(46.0–77.8) |
gender (male/female) | 29/20 |
head/body-tail | 32/17 |
radiographic arterial involvement | Â |
celiac artery | 4 |
common hepatic artery | 9 |
replaced RHA | 2 |
superior mesenteric artery | 34 |
BRPV/without BRPV | 28/21 |
radiological tumor size (mm) | 25.7(15.0–47.0) |
CEA before NACIMRT (U/ml) | 3.0(0.5–114.9) |
CA19-9 before NACIMRT (U/ml) | 111.4(0.6–2451) |
NL ratio before NACIMRT | 2.55(1.0–10.0) |
SUV max before NACIMRT | 6.4(2.2–15.8) |
NAC incompletion due to adverse event | 2/49(4.1%) |
Post NACIMRT (at re-assessment after NACIMRT) | n = 47 |
radiological tumor size after NACIMRT (mm) | 21.5(11.7–50.1) |
CEA after NACIMRT (U/ml) | 3.0(0.7–57.6) |
CA19-9 after NACIMRT (U/ml) | 36.7(0.6–2298) |
NL ratio after NACIMRT | 3.04(0.81–11.86) |
SUV max after NACIMRT | 4.35(1.9–10.4) |
RECIST > PR | 13/47(27.6%) |
G3/4 adverse event | 10/47(21.3%) |